PARIS & VILLEJUIF, France--(BUSINESS WIRE)--Regulatory News: IPSEN (Paris:IPN) (Euronext: IPN; ADR: IPSEY), a global biopharmaceutical company represented by Claude Bertrand, Executive Vice President, R&D and Chief Scientific Officer, and Institut de cancérologie Gustave Roussy (IGR, Villejuif), a leading international cancer center represented by Professor Alexander Eggermont, General Director, today announced the signature of a partnership in the area of medical oncology to leverage the combined expertises of their respective R&D teams. This 3 year agreement was signed on 27 June 2011.
